Compare TTMI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | CORT |
|---|---|---|
| Founded | 1978 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 9.7B |
| IPO Year | 2000 | 2001 |
| Metric | TTMI | CORT |
|---|---|---|
| Price | $125.60 | $111.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $127.25 | $96.50 |
| AVG Volume (30 Days) | ★ 2.6M | 731.0K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 211.11 | N/A |
| EPS | ★ 1.24 | 0.09 |
| Revenue | ★ $2,906,345,000.00 | $761,407,000.00 |
| Revenue This Year | $18.60 | $26.08 |
| Revenue Next Year | $16.91 | $26.98 |
| P/E Ratio | ★ $93.93 | $1,269.56 |
| Revenue Growth | ★ 18.98 | 12.79 |
| 52 Week Low | $45.73 | $28.66 |
| 52 Week High | $223.83 | $126.38 |
| Indicator | TTMI | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 54.11 |
| Support Level | $87.36 | $77.73 |
| Resistance Level | $129.51 | $124.30 |
| Average True Range (ATR) | 7.06 | 4.38 |
| MACD | 0.44 | -1.79 |
| Stochastic Oscillator | 32.09 | 31.35 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.